// App-Quantinova.ai

8008 : FDA analysis of pembrolizumab trials in multiple myeloma: Immune related adverse events (irAEs) and response.

Researchers

Presenter

  • Aviva C Krauss

Principal Investigators

  • Flora Mulkey

  • Yuan-Li Shen

  • Amy Rosenberg

  • Barry Miller

  • Theresa Carioti

  • Kimberly Scott

  • Nicole Gormley

  • Marc Robert Theoret

  • Rajeshwari Sridhara

  • Ann T. Farrell

  • Richard Pazdur

Medical Centers

  • U.S. Food and Drug Administration, Silver Spring, MD

  • U.S. Food and Drug Administration, Silver Spring, MD

  • National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

  • U.S. Food and Drug Administration, Bethesda, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pembrolizumab

  • Pomalidomide

  • CC-4047

  • Lenalidomide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved